Rao, Circuit Judge:
Under the Hatch-Waxman Act, a drug may receive "new chemical entity exclusivity" if no active ingredient in the drug was previously "approved." The drug Aubagio was awarded this exclusivity because the Food & Drug Administration ("FDA") determined that Aubagio's only active ingredient, teriflunomide, had never previously...
Let's get started
Welcome to the leading source of independent legal reporting
Sign on now to see your case.
Or view more than 10 million decisions and orders.
- Updated daily.
- Uncompromising quality.
- Complete, Accurate, Current.